domingo, 9 de agosto de 2015

Colorectal Cancer Identification Methods Among Kansas Medicare Beneficiaries, 2008–2010

full-text ►

Colorectal Cancer Identification Methods Among Kansas Medicare Beneficiaries, 2008–2010



CDC. Centers for Disease Control and Prevention. CDC 24/7: Saving Lives. Protecting People.





PCD logo



Colorectal Cancer Identification Methods Among Kansas Medicare Beneficiaries, 2008–2010

Sue-Min Lai, PhD, MS, MBA; Jessica Jungk, MS, MPH; Sarma Garimella, MBBS, MPH

Suggested citation for this article: Lai S, Jungk J, Garimella S. Colorectal Cancer Identification Methods Among Kansas Medicare Beneficiaries, 2008–2010. Prev Chronic Dis 2015;12:140543. DOI:http://dx.doi.org/10.5888/pcd12.140543.
PEER REVIEWED

Abstract

Introduction
Population-based data are limited on how often colorectal cancer (CRC) is identified through screening or surveillance in asymptomatic patients versus diagnostic workup for symptoms. We developed a process for assessing CRC identification methods among Medicare-linked CRC cases from a population-based cancer registry to assess identification methods (screening/surveillance or diagnostic) among Kansas Medicare beneficiaries.
Methods
New CRC cases diagnosed from 2008 through 2010 were identified from the Kansas Cancer Registry and matched to Medicare enrollment and claims files. CRC cases were classified as diagnostic-identified versus screening/surveillance-identified using a claims-based algorithm for determining CRC test indication. Factors associated with screening/surveillance-identified CRC were analyzed using logistic regression.
Results
Nineteen percent of CRC cases among Kansas Medicare beneficiaries were screening/surveillance-identified while 81% were diagnostic-identified. Younger age at diagnosis (65 to 74 years) was the only factor associated with having screening/surveillance-identified CRC in multivariable analysis. No association between rural/urban residence and identification method was noted.
Conclusion
Combining administrative claims data with population-based registry records can offer novel insights into patterns of CRC test use and identification methods among people diagnosed with CRC. These techniques could also be extended to other screen-detectable cancers.
Identification method classification process and results for invasive colorectal cancer (CRC), Kansas Medicare beneficiaries, 2008–2010. “Ko algorithm” refers to classification and regression tree algorithm for colonoscopy indication (diagnostic vs average-risk screening/high-risk screening/surveillance) developed by Ko
Figure. Identification method classification process and results for invasive colorectal cancer (CRC), Kansas Medicare beneficiaries, 2008–2010. “Ko algorithm” refers to classification and regression tree algorithm for colonoscopy indication (diagnostic vs average-risk screening/high-risk screening/surveillance) developed by Ko et al (10). [A text description of this figure is also available.]

Acknowledgments

This project was supported by the Kansas Department of Health and Environment and the National Program of Cancer Registries from CDC agreement no. U58/DP003889.
 Top

Author Information

Corresponding Author: Sue-Min Lai, PhD, MS, MBA, Kansas Cancer Registry, Department of Preventive Medicine and Public Health, University of Kansas Medical Center, Mail Stop 1008, 3901 Rainbow Blvd, Kansas City, KS 66160-7313. Telephone: 913-588-2744. Email: slai@kumc.edu.
Author Affiliations: Jessica Jungk, Sarma Garimella, Kansas Cancer Registry, Department of Preventive Medicine and Public Health, University of Kansas Medical Center, Kansas City, Kansas.
 Top

References

  1. Kansas Cancer Registry. Multiple year report, cancer incidence in Kansas 2001–2010. http://www.kumc.edu/kcr/reports.aspx. Accessed October 1, 2014.
  2. US Preventive Services Task Force. Screening for colorectal cancer: recommendation and rationale. Ann Intern Med 2002;137(2):129–31. CrossRef PubMed
  3. Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the US Preventive Services Task Force. Ann Intern Med 2002;137(2):96–104. CrossRef PubMed
  4. Klabunde CN, Cronin KA, Breen N, Waldron WR, Ambs AH, Nadel MR. Trends in colorectal cancer test use among vulnerable populations in the United States. Cancer Epidemiol Biomarkers Prev 2011;20(8):1611–21. CrossRef PubMed
  5. Centers for Disease Control and Prevention. Cancer screening — United States, 2010. MMWR Morb Mortal Wkly Rep 2012;61(3):41–5. PubMed
  6. Shapiro JA, Klabunde CN, Thompson TD, Nadel MR, Seeff LC, White A. Patterns of colorectal cancer test use, including CT colonography, in the 2010 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev 2012;21(6):895–904. CrossRef PubMed
  7. American Cancer Society. Cancer prevention and early detection facts and figures 2013. Atlanta (GA): American Cancer Society; 2013.
  8. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010;116(3):544–73. CrossRef PubMed
  9. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al. , editors. SEER Cancer Statistics Review, 1975–2010. Bethesda (MD): National Cancer Institute; 2013. http://seer.cancer.gov/csr/1975_2010. Accessed October 15, 2013.
  10. Ko CW, Dominitz JA, Neradilek M, Polissar N, Green P, Kreuter W, et al. Determination of colonoscopy indication from administrative claims data. Med Care 2014;52(4):e21–9. Published online March 23, 2012. CrossRef PubMed
  11. Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 2007;17(8):584–90. CrossRef PubMed
  12. SEER-Medicare: calculation of comorbidity weights. Bethesda (MD): National Cancer Institute. http://healthservices.cancer.gov/seermedicare/program/comorbidity.html. Accessed March 1, 2013.
  13. RUCA Zip code approximation. Seattle (WA): Rural Health Research Center, University of Washington. http://depts.washington.edu/uwruca/ruca-download.php. Accessed March 1, 2013.
  14. Amri R, Bordeianou LG, Sylla P, Berger DL. Impact of screening colonoscopy on outcomes in colon cancer surgery. JAMA Surg 2013;148(8):747–54. CrossRef PubMed
  15. McConnell YJ, Inglis K, Porter GA. Timely access and quality of care in colorectal cancer: are they related? Int J Qual Health Care 2010;22(3):219–28. CrossRef PubMed
  16. Cancer Patient Data Program. SEER 1997: Seattle case completeness and data validity audit [review]. San Francisco (CA): University of California, San Francisco; 1998.
  17. National Program of Cancer Registries data quality evaluation: Kansas Cancer Registry. Atlanta (GA): National Program of Cancer Registries, Centers for Disease Control and Prevention; 2010.
  18. Schenck AP, Klabunde CN, Warren JL, Peacock S, Davis WW, Hawley ST, et al. Data sources for measuring colorectal endoscopy use among Medicare enrollees. Cancer Epidemiol Biomarkers Prev 2007;16(10):2118–27. CrossRef PubMed
  19. Nattinger AB, Schapira MM, Warren JL, Earle CC. Methodological issues in the use of administrative claims data to study surveillance after cancer treatment. Med Care 2002;40[supplement]:IV–69–IV–74. PubMed
  20. US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 2008;149(9):627–37. CrossRefPubMed
  21. Wee CC, McCarthy EP, Phillips RS. Factors associated with colon cancer screening: the role of patient factors and physician counseling. Prev Med 2005;41(1):23–9. CrossRef PubMed
  22. Guerra CE, Schwartz JS, Armstrong K, Brown JS, Halbert CH, Shea JA. Barriers of and facilitators to physician recommendation of colorectal cancer screening. J Gen Intern Med 2007;22(12):1681–8. CrossRef PubMed
  23. Klabunde CN, Schenck AP, Davis WW. Barriers to colorectal cancer screening among Medicare consumers. Am J Prev Med 2006;30(4):313–9. CrossRef PubMed

No hay comentarios: